SARS-CoV-2 Postvaccination Infections Among Staff Members of a Tertiary Care University Hospital – Vienna, January-July 2021; an Exploratory Study on 8 500 Employees with Better Outcome of Vector than m-RNA Vaccine
| Autor: | Helene Resch, Florian Thalhammer, Sophie Brunner, Bernhard Parschalk, Andrea Foit, Maximilian Schnetzinger, Robert Strassl, Tibor Spath, Gabriela Kornek, Rebeka Savic |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
History
Pediatrics medicine.medical_specialty Polymers and Plastics business.industry Incidence (epidemiology) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Exploratory research Breakthrough infection Asymptomatic Industrial and Manufacturing Engineering Vaccination Immunization Medicine Vector (molecular biology) Business and International Management medicine.symptom business |
| Zdroj: | SSRN Electronic Journal. |
| ISSN: | 1556-5068 |
| DOI: | 10.2139/ssrn.3907198 |
| Popis: | Background: The identification of SARS-CoV-2 antigen or RNA in a respiratory specimen collected from a person ≥14 days after completing all recommended doses of authorized COVID-19 vaccine series is a rare condition and defined as „breakthrough infection“. Data on mildly symptomatic or asymptomatic SARS-CoV-2 vaccine breakthrough infection cases especially with respect to viral characteristics and temporal relation to vaccination date is scarce. The purpose of the present investigation was to investigate the prevalence of postvaccination infections in hospital employees and to compare between m-RNA and vector based SARS-CoV-2 vaccines. Methods: At the General Hospital of Vienna 8 553 actively employed staff members participated at an voluntary in-house vaccination program, which took place between January and May 2021 and comprised of application of two doses of either COMIRNATY (BNT162b2; Pfizer/BioNTech, Inc.) or VAXZEVRIA (AstraZeneca, Inc.). Findings: By the end of July 2021 a total of 78 postvaccination infection cases after administration of a minimum of one dose of vaccination had been identified (median age: 40·5 years (IQR: 19-60 years); 53 women) of whom 53 had been vaccinated with VAXZEVRIA and 25 with COMIRNATY. The majority of infections was related to an insufficient or partial vaccination status; the incidence of postvaccination infection ≥14 days after complete vaccination (i.e. breakthrough infection) was 34·8: 10 000 for COMIRNATY and 8·8: 10 000 for VAXZEVRIA. There was no difference in PCR-CT values between the two vaccine brands (24·67 (SD: 7·41) for VAXZEVRIA vaccinated versus 24·0 (SD: 6·53) for COMIRNATY vaccinated persons). Genotyping of positive PCR specimens revealed 42 variant of concerns: B.1.1.7 (n=34); B.1.351 (n=2), B.1.617.2 (n=6). The prevalence of „real brakthrough infections“ (≥14 days after second vaccination) was higher in COMIRNATY vaccinated subjects than in the VAXZEVRIA vaccinated subjects with a ratio of 14:4 (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|